Table 3. Meta-analysis results by ethnicity.
Outcome | Ethnicity | N^ | Patients, n | Mut&, (%) | Fixed | Random | Heterogeneity | Subgroup Differences | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AML | RRs* 95%CI | RRs 95%CI | P | I2 | Fixed | Random | ||||||
P | I2 | P | I2 | |||||||||
CR | ||||||||||||
t(8,21) | ||||||||||||
Caucasian | 4 | 411 | 82(20) | 0.61 [0.19, 1.95] | 0.70 [0.21, 2.30] | 0.73 | 0% | |||||
non-Caucasian | 5 | 315 | 115(37) | 2.03 [1.02, 4.05] | 2.06 [1.01, 4.22] | 0.41 | 0% | 0.08 | 67% | 0.13 | 57% | |
inv(16) | ||||||||||||
Caucasian | 5 | 527 | 166(31) | 0.80 [0.41, 1.59] | 0.87 [0.43, 1.77] | 0.51 | 0% | |||||
non-Caucasian | 4 | 127 | 40(31) | 1.96 [0.50, 7.72] | 2.13 [0.47, 9.68] | 0.31 | 3% | 0.25 | 23% | 0.30 | 9% | |
OS | ||||||||||||
t(8,21) | ||||||||||||
Caucasian | 3 | 362 | 71(20) | 1.12 [0.90, 1.40] | 1.06 [0.80, 1.40] | 0.26 | 27% | |||||
non-Caucasian | 3 | 136 | 42(31) | 2.26 [1.35, 3.78] | 2.22 [1.33, 3.70] | 0.82 | 0% | 0.01 | 84% | 0.01 | 84% | |
inv(16) | ||||||||||||
Caucasian | 5 | 527 | 166(31) | 1.02 [0.88, 1.18] | 1.01 [0.83, 1.25] | 0.12 | 45% | |||||
non-Caucasian | 3 | 110 | 32(29) | 1.08 [0.79,1.47] | 1.01 [0.74, 1.36] | 0.34 | 7% | 0.75 | 0% | 0.97 | 0% | |
Relapse Risk | ||||||||||||
t(8,21) | ||||||||||||
5y | Caucasian | 3 | 341 | 75(22) | 1.55 [1.10, 2.18] | 1.60 [1.14, 2.23] | 0.70 | 0% | ||||
2y | non-Caucasian | 5 | 278 | 96(35) | 1.89 [1.51, 2.37] | 1.91 [1.41, 2.57] | 0.26 | 24% | ||||
4y | non-Caucasian | 3 | 123 | 34(28) | 2.33 [1.59, 3.41] | 2.87 [1.15, 7.15] | 0.16 | 45% | ||||
5y | non-Caucasian | 2 | 77 | 26(34) | 2.03 [1.37, 3.01] | 2.00 [1.35, 2.96] | 0.58 | 0% | 0.34 | 0% | 0.44 | 0% |
inv(16) | ||||||||||||
5y | Caucasian | 3 | 286 | 83(29) | 1.18 [0.92, 1.52] | 1.22 [0.78, 1.90] | 0.11 | 55% | ||||
non-Caucasian | 3 | 101 | 28(28) | 0.94 [0.56, 1.58] | 0.57 [0.10, 3.45] | 0.07 | 52% | 0.44 | 0% | 0.43 | 0% |
^ N: Studies included.
* ORs for CR, and RRs for OS and relapse rate.
& Numbers of patients with KIT-mutations.